Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment
Files
Publication date
2017-01-12
Authors
Zittema, Debbie
Casteleijn, Niek F.
Bakker, Stephan J. L.
Boesten, Lianne S M
Duit, A A Margreeth
Franssen, Casper F. M.
Gaillard, Carlo A J M
Gansevoort, Ron T.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
BACKGROUND: Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine concentrating capacity. Increased circulating vasopressin (AVP) concentrations are supposed to play a role in the progression of ADPKD. We hypothesized that ADPKD patients have a more severely impaired urine concentrating capacity in comparison to other patients with chronic kidney disease at a similar level of kidney function, with consequently an enhanced AVP response to water deprivation with higher circulating AVP concentrations.METHODS: 15 ADPKD (eGFR
Keywords
ANTAGONISTS, CYSTIC-DISEASE, DEFECTS, OSMOREGULATION, PLASMA COPEPTIN, POLYCYSTIC KIDNEY-DISEASE, UREA, Journal Article, Clinical Trial
Citation
Zittema, D, Casteleijn, N F, Bakker, S J L, Boesten, L S M, Duit, A A M, Franssen, C F M, Gaillard, C A J M & Gansevoort, R T 2017, 'Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment', PLoS ONE [E], vol. 12, no. 1, e0169263. https://doi.org/10.1371/journal.pone.0169263